Illumina Oncology – Liquid biopsy NGS in cancer care

27 April 2023

Pashtoon Kasi, MD, MS, explains how liquid biopsy next-generation-sequencing (NGS)-based testing can benefit cancer patients. Dr. Kasi presents four colorectal cancer patient cases for whom comprehensive genomic profiling was done via liquid biopsy and results for clinically -relevant biomarkers were obtained in seven to eight days. Dr. Kasi is the director of Colon Cancer Research and director of Precision Medicine Research for Liquid Biopsies at Weill Cornell Medicine. Listen to the podcast episode to learn about minimal residual disease (MRD): https://www.illumina.com/science/genomics-podcast/liquid-biopsy-ngs-in-cancer-care.html Learn about Homologous Recombination Deficiency (HRD) testing in ovarian cancer: https://youtu.be/54yI7Sxvnfc Learn about when to test for NTRK fusions: https://youtu.be/0zeO1oz6tbE The Illumina Oncology series is brought to you by Medical Affairs. M-GL-01706 Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM Facebook: https://www.facebook.com/illuminainc LinkedIn: https://www.linkedin.com/company/illumina Instagram: https://www.instagram.com/illuminainc/ Twitter: https://twitter.com/illumina #liquidbiopsy #circulatingtumorcells #circulatingtumorDNA #cancerNGS #bloodtest #microsatelliteinstability #mrd #comprehensivegenomicprofiling #genepanel #CHIP #minimalresidualdisease

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.